Chen P., Poddar R., Tipa E.V., Dibello P.M., Moravec C.D., Robinson K., Green R.,Kruger W.D., Garrow T.A., Jacobsen D.W. : Homocysteine metabolism in cardiovascular cells and tissues: implications for hyperhomocysteinemia and cardiovascular disease. Adv Enzyme Regul, 1999, 39, 93-109.
DOI: https://doi.org/10.1016/S0065-2571(98)00029-6
Irizarry M.C., Gurol M.E., Raju S., Diaz-Arrastia R., Locascio J.J., Tennis M., Hyman B.T., Growdon J.H., Greenberg S.M., Bottiglieri T.: Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease. Neur, 2005, 65(9),1402-8.
DOI: https://doi.org/10.1212/01.wnl.0000183063.99107.5c
Rosenquist T.H., Ratashak S.A., Selhub J.: Homocysteine induces congenital defects of the heart and neural tube: effect of folic acid. Proc Natl Acad Sci, 1996, 93, 15227-15232.
DOI: https://doi.org/10.1073/pnas.93.26.15227
Akoglu B., Milovic V., Caspary W.F., Faust D.: Hyperproliferation of homocysteine-treated colon cancer cells is reversed by folate and 5-methyltetrahydrofolate. Eur J Nutr, 2004, 43,93-9.
DOI: https://doi.org/10.1007/s00394-004-0446-6
Mitchell T.: Methylation a little-known but essential process. Life Extension sierpień 1998, dostępna pod adresem: www.lef.org/magazine/mag98/aug98-report2.html
Medina M., Urdiales J.L., Amores-Sanchez M.L.: Roles of homocysteine in cell metabolism: old and new functions. Eur J. Biochem. 2001, 268,3871-82.
DOI: https://doi.org/10.1046/j.1432-1327.2001.02278.x
Bailey L.B., Gregory J.F.: Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: metabolic significance, risks and impact on folate requirement. J Nutr, 1999, 129, 919-922.
DOI: https://doi.org/10.1093/jn/129.5.919
Brattström L., Wilcken DE., Ohrvik J., Brudin L.: Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: The result of a meta-analysis. Circulation, 1998, 98, 2520-2526.
DOI: https://doi.org/10.1161/01.CIR.98.23.2520
Bilwani F., Syed N.A., Usman M., Khurshid M.: Familial homocystinuria. J Coll Physicians Surg Pak, 2005,15, 106-7.
Jakubowski H.: Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J, 1999, 13, 2277-2283.
DOI: https://doi.org/10.1096/fasebj.13.15.2277
Jakubowski H.: Protein N-homocysteinylation: implications for atherosclerosis, Biomed Pharmacother, 2001, 55, 443-447.
DOI: https://doi.org/10.1016/S0753-3322(01)00085-3
Hoogeveen E.K., Kostense P.J., Jakobs C., Dekker J.M., Nijpels G., Heine R.J., Bouter L.M., Stehouwer C.D.: Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study. Circulation 2000, 101, 1506-1511.
DOI: https://doi.org/10.1161/01.CIR.101.13.1506
Wang H., Yoshizumi M., Lai K., Tsai J.C., Perrella M.A., Haber E., Lee M.E. Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem, 1997, 272, 25380-25385.
DOI: https://doi.org/10.1074/jbc.272.40.25380
Tsai J.T., Wang H., Perrella M.A., Yoshizumi M., Sibinga N.E.S., Tan L.C., Haber E., Chang T.H.T., Schlegel R., Lee M.E.: Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J Clin Invest, 1996, 97, 146-153.
DOI: https://doi.org/10.1172/JCI118383
Gaciong Z.: Nadciśnienie tętnicze, hiperhomocysteinemia i kwas foliowy. Czynniki Ryzyka, 2005, supl.11, 11.
Szczeklik A.,Undas A.: Homocysteina w żylnej chorobie zakrzepowo-zatorowej. Czynniki Ryzyka, 2005, supl. 11, 14-15.
Jakubowski H.: Metabolism of homocysteine thiolactone in human cell cultures: possible mechasmism for pathological consequences of elevated homocysteine levels. J Biol Chem,1997, 272, 1935-1942.
DOI: https://doi.org/10.1016/S0021-9258(19)67504-6
Ryglewicz D.,Graban A.: Zaburzenia metabolizmu homocysteiny w chorobach zwyrodnieniowych ośrodkowego układu nerwowego.Czynniki Ryzyka, 2005, supl.11,20-22.
Zhu B.T.: Medical hypothesis: hyperhomocysteinemia is a risk factor for estrogen-induced hormonal cancer. Int J Oncol, 2003 Mar;22(3):499-508.
Kozłowska-Wojciechowska M.: Jak zapobiegać hiperhomocysteinemii? Naturalne źródła folianów i witamin z grupy B w polskiej diecie. Czynniki Ryzyka, 2005,supl.11,25-26.
Zalecenia Polskiego Towarzystwa Badań Nad Miażdżycą, http://www.dach-liga-homocystein.org.